Manufacturers looking to stay out of regulatory hot water for conveying the off-label uses of their medical products to health care professionals (HCPs) should consult new final guidance from the Food and Drug Administration.
The agency’s document offers manufacturers a series of Q&As that seek to clarify the regulatory parameters for describing off-label uses...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?